logo

Kala Pharmaceuticals, Inc. (KALA)



Trade KALA now with
  Date
  Headline
8/7/2019 8:52:04 AM Wedbush Is Cutting Kala Pharmaceuticals, Inc. (KALA) FY20 Rev. Estimate To 35.1 M From 54.7 M
8/7/2019 8:51:51 AM Wedbush Is Cutting Kala Pharmaceuticals, Inc. (KALA) Q4 20 Rev. Estimate To 12.5 M From 28.0 M
8/7/2019 8:51:39 AM Wedbush Is Lowering Kala Pharmaceuticals, Inc. (KALA) Q3 20 Rev. Estimate To 9.7 M From 13.8 M
8/7/2019 8:51:21 AM Wedbush Is Cutting Kala Pharmaceuticals, Inc. (KALA) FY19 Rev. Estimate To 10.9 M From 11.2 M
8/7/2019 8:50:55 AM Wedbush Is Cutting Kala Pharmaceuticals, Inc. (KALA) FY20 Estimate To -2.64 From -2.40
8/7/2019 8:50:43 AM Wedbush Is Cutting Kala Pharmaceuticals, Inc. (KALA) Q4 20 Estimate To -0.61 From -0.28
8/7/2019 8:50:30 AM Wedbush Is Cutting Kala Pharmaceuticals, Inc. (KALA) Q3 20 Estimate To -0.68 From -0.65
8/7/2019 8:50:19 AM Wedbush Is Increasing Kala Pharmaceuticals, Inc. (KALA) Q2 20 Estimate To -0.68 From -0.75
8/7/2019 8:50:07 AM Wedbush Is Raising Kala Pharmaceuticals, Inc. (KALA) Q1 20 Estimate To -0.67 From -0.73
8/7/2019 8:49:55 AM Wedbush Is Raising Kala Pharmaceuticals, Inc. (KALA) FY19 Estimate To -2.69 From -2.84
8/7/2019 8:49:42 AM Wedbush Is Increasing Kala Pharmaceuticals, Inc. (KALA) Q4 19 Estimate To -0.62 From -0.70
8/7/2019 8:49:30 AM Wedbush Is Increasing Kala Pharmaceuticals, Inc. (KALA) Q3 19 Estimate To -0.62 From -0.69
8/7/2019 8:48:54 AM Wedbush Reiterates Kala Pharmaceuticals, Inc. (KALA) At Outperform With $51 Price Target
1/7/2019 7:07:06 AM Kala Pharmaceuticals Announces The Launch Of INVELTYS
12/26/2018 7:02:34 AM Kala Says NDA For KPI-121 0.25% For Dry Eye Disease Accepted For Review By FDA
11/8/2018 7:45:06 AM Kala Pharmaceuticals Q3 Net Loss $15.6 Mln Or $0.63/Shr Vs Net Loss $10.2 Mln Or $0.56/Shr Last Year
10/16/2018 8:06:25 AM Kala Pharma Submits NDA For KPI-121 0.25% For Dry Eye Disease
10/3/2018 8:04:17 AM Kala Pharmaceuticals Prices Public Offering Of 7.50 Mln Shares At $8.25 Per Share